Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We have retained our Neutral recommendation on DENTSPLY International Inc. (XRAY - Analyst Report) with a price target of $42.
Its third-quarter 2012 adjusted earnings per share of 51 cents inched past the Zacks Consensus Estimate of 50 cents per share and exceeded the year-ago adjusted earnings of 46 cents (up 10.9%).
Revenues jumped 12.3% year over year to $695.7 million, driven by acquisitions and strong internal sales in the U.S., Europe as well as the Rest of World categories. However, revenues fell short of the Zacks Consensus Estimate of $712 million.
Led by the prevailing macroeconomic scenario and the company’s performance, DENTSPLY expects to generate adjusted earnings per share in the band of $2.19–$2.24 for 2012, compared with the earlier band of $2.18—$2.24.
Based in Pennsylvania, DENTSPLY International is a global leader in the design, development, manufacture and marketing of dental consumables, dental laboratory products and dental specialty products. Despite macroeconomic headwinds, it boasts solid internal growth on the back of innovative new products and consistent strong performance.
The company also has a strong international presence. Emerging markets offer healthy growth opportunity on a long-term basis as they remain vastly untapped.
Further, the acquisition of Astra Tech has reinforced the company’s leadership in the global dental market and broadened its product portfolio. DENTSPLY is successfully integrating the acquired operation.
Moreover, the re-launch program of the orthodontics products line is gathering momentum and we expect it to gain market share and boost internal growth going forward.
However, an overall soft macro economy, especially a slow global dental implants market, remains a potential downside for DENTSPLY. Austerity measures in southern Europe due to geopolitical uncertainty also remain a concern.
Although the company’s domestic U.S. market has shown signs of recovery lately, demand for dental products are slow mainly due to the troubled U.S. labor market, currency fluctuation and the upcoming Med-tech tax.
DENTSPLY operates in highly competitive markets and hence, we remain cautious about the aggressive competition from players like Sirona Dental Systems (SIRO - Snapshot Report). We currently have a short-term Zacks #3 Rank (Hold) on DENTSPLY.
Get the full Analyst Report on XRAY - FREE
Get the full Snapshot Report on SIRO - FREE